Jun 30, 2022 / 12:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Lexicon Pharmaceuticals, Inc. Top Line Results for LX9211 Conference Call. (Operator Instructions) This call is being recorded today, Thursday, June 30, 2022. And I would now like to turn the conference over to Mr. Michael O'Kelly. Please go ahead, sir.
Unidentified Company Representative -
Thank you, Michelle. Good morning, and welcome to Lexicon Pharmaceuticals conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; and Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer. Yesterday afternoon, Lexicon issued a press release reporting positive top line results from our RELIEF-DPN-1 Phase II proof-of-concept study of LX9211 in painful diabetic neuropathy, which is available on our website at www.lexpharma.com.
A webcast of this call, along with the slide presentation is available on our website.
During this call, we
Lexicon Pharmaceuticals Inc RELIEF-DPN-1 Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot